Regeneron Pharmaceuticals Aktie
WKN: 881535 / ISIN: US75886F1075
21.08.2024 03:23:41
|
FDA Issues Complete Response Letter For Regeneron's Linvoseltamab In R/R Multiple Myeloma
(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) said that the U.S. Food and Drug Administration has issued a Complete Response Letter or CRL for the Biologics License Application or BLA for linvoseltamab in relapsed/refractory multiple myeloma that has progressed after at least three prior therapies.
According to the company, the sole approvability issue identified is related to findings from a pre-approval inspection at a third-party fill/finish manufacturer for another company's product candidate.
For More Such Health News, visit rttnews.com.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Regeneron Pharmaceuticals Inc.mehr Nachrichten
Analysen zu Regeneron Pharmaceuticals Inc.mehr Analysen
Aktien in diesem Artikel
Regeneron Pharmaceuticals Inc. | 482,00 | -0,47% |
|